Showing results (941-950 of 977) with videos related to

Sort By:
Pageof 98
NPJ Breast Cancer|February 13, 2026
Evaluation of methods to classify ipsilateral breast tumour recurrences as local recurrence or new primary tumourS Blacker, K Horgan, D A Cromwell, et al.
NPJ Breast Cancer|January 28, 2026
Outcomes of a prospective cohort study of PREoperative therapy and supportive care in early & locally advanced breast cancers-PreSCella studyHan Yi Lee, Whee Sze Ong, Jasmine Yun Ting Tan, et al.
NPJ Breast Cancer|February 13, 2026
Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancerPaolo Tarantino, Jaeyoon Cha, Busem Binboga Kurt, et al.
NPJ Breast Cancer|August 1, 2025
Selection biases in the systematic collection of breast biobank specimensYael Bar, Gary X Wang, Gabrielle E Gioia, et al.
NPJ Breast Cancer|June 21, 2025
The MBCRC Advocate Researcher Program (MARP): connecting advocates and researchers as collaborative partners in cancer researchHillary S Andrews, Igor L Bado, Amy Beumer, et al.
NPJ Breast Cancer|April 25, 2025
Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and responseShiran Yaacobi Peretz, Rivka Kessner, Yael Bar, et al.
NPJ Breast Cancer|June 2, 2023
Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort studyOfer Rotem, Idit Peretz, Michelle Leviov, et al.
NPJ Breast Cancer|February 24, 2026
Transcriptomic analysis to uncover the mechanism of radiosensitization of AR-positive triple-negative breast cancers with AR inhibitionBreanna McBean, Benjamin Hauk, Anna R Michmerhuizen, et al.
NPJ Breast Cancer|March 2, 2026
Heterogeneity and immune microenvironment of early invasive estrogen receptor-positive breast cancer reveal an immune-rich subsetDrashti Jain, Linda Liao, Vida Talebian, et al.
NPJ Breast Cancer|June 28, 2023
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancerGiuseppe Curigliano, Rebecca Dent, Antonio Llombart-Cussac, et al.
Pageof 98